Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial

International Journal of Cancer

Volumn 140, Issue 3, 2017, Pages 600-610

  Trabert, Britton ^a   Eldridge, Ronald C ^a   Pfeiffer, Ruth M ^a   Shiels, Meredith S ^a   Kemp, Troy J ^b   Guillemette, Chantal ^c   Hartge, Patricia ^a   Sherman, Mark E ^a   Brinton, Louise A ^a   Black, Amanda ^a   Chaturvedi, Anil K ^a   Hildesheim, Allan ^a   Berndt, Sonja I ^a   Safaeian, Mahboobeh ^a   Pinto, Ligia ^a,b   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

circulating inflammation markers; endometrial cancer; nested case contro; prediagnostic

Indexed keywords

ACUTE PHASE PROTEIN; ADIPOCYTOKINE; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CYTOKINE; ESTRADIOL; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1; UNCLASSIFIED DRUG; VASCULOTROPIN A; TUMOR MARKER;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; COLORECTAL NEOPLASMS; COMPLICATION; EARLY CANCER DIAGNOSIS; ENDOMETRIAL NEOPLASMS; LUNG NEOPLASMS; MALE; METABOLISM; ODDS RATIO; OVARIAN NEOPLASMS; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADIPOKINES; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOKINES; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; ODDS RATIO; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84999036899     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30478     Document Type: Article

References (28)

1. Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol 2014;10:2561–8.
2. Brinton L, Sahasrabuddhe VV, Trabert B. Epidemiology of gynecologic cancers. In: Barakat R, Berchuck A, Markman M, Randall ME, eds. Principles and practice of gynecologic oncologyed., vol. 6. Philadelphia, PA: Lippincott Williams & Wilkins, 2013. 1–29.
3. Modugno F, Ness RB, Chen C, et al. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomark Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2005;14:2840–7.
4. Kelly RW, King AE, Critchley HO. Cytokine control in human endometrium. Reproduction 2001;121:3–19.
5. Dossus L, Rinaldi S, Becker S, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocrine-Related Cancer 2010;17:1007–19.
6. Dossus L, Becker S, Rinaldi S, et al. Tumor necrosis factor (TNF)-alpha, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer J Int Cancer 2011;129:2032–7.
7. Wang T, Rohan TE, Gunter MJ, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2011;20:971–7.
8. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007;92:255–63.
9. Luhn P, Dallal CM, Weiss JM, et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2013;22:1304–12.
10. Soliman PT, Cui X, Zhang Q, et al. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol 2011;204:167 e1–5.
11. Dallal CM, Brinton LA, Bauer DC, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B∼FIT cohort. Endocr Related Cancer 2013;20:151–60.
12. Kitahara CM, Trabert B, Katki HA, et al. Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2014;23:2840–9.
13. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S–309S.
14. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005;592:147–54.
15. Chaturvedi AK, Kemp TJ, Pfeiffer RM, et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomark Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2011;20:1902–11.
16. Karim R, Stanczyk FZ, Hodis HN, et al. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 2010;17:785–90.
17. Howe LR, Subbaramaiah K, Hudis CA, et al. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2013;19:6074–83.
18. Zyla MM, Kostrzewa M, Litwinska E, et al. The role of angiogenic factors in endometrial cancer. Prz Menopauzalny 2014;13:122–6.
19. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883–99.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.
22. Dapunt U, Maurer S, Giese T, et al. The macrophage inflammatory proteins MIP1alpha (CCL3) and MIP2alpha (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation. Mediators Inflamm 2014;2014:728619.
23. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008;181:5948–55.
24. Bailey SR, Nelson MH, Himes RA, et al. Th17 cells in cancer: the ultimate identity crisis. Front Immunol 2014;5:276.
25. Pischon T, Hankinson SE, Hotamisligil GS, et al. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003;11:1055–64.
26. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 2009;55:305–12.
27. Epstein MM, Breen EC, Magpantay L, et al. Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomark Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol 2013;22:2009–15.
28. Gu Y, Zeleniuch-Jacquotte A, Linkov F, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44–9.